New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 1228-1236

  Moreau, Pascale ^a,b   Dezhenkova, Lyubov G ^c   Anizon, Fabrice ^a,b   Nauton, Lionel ^a,b   Théry, Vincent ^a,b   Liang, Shuguang ^d   Kaluzhny, Dmitry N ^e   Shtil, Alexander A ^f,g  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b ICCF   (France)

^c GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^d REACTION BIOLOGY CORPORATION   (United States)

^e ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^f N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^g NATIONAL RESEARCH NUCLEAR UNIVERSITY MEPHI   (Russian Federation)

Author keywords

Anticancer therapy; Colon carcinoma; Pim kinases; Serine threonine protein kinases; Small molecular weight inhibitors

Indexed keywords

CYCLINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 3; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBAZOLE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; ONCOPROTEIN; PIM2 PROTEIN, HUMAN; PIM3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTO-ONCOGENE PROTEINS PIM; PYRROLE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; MTT ASSAY; QUANTITATIVE ASSAY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CARBAZOLES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HUMANS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-PIM-1; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE INHIBITORS;

EID: 84911471663     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140825124456     Document Type: Article

References (50)

1. Blanco-Aparicio, C.; Carnero, A. Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. Biochem. Pharmacol., 2013, 85, 629-643.
2. Nawijn, M.C.; Alendar, A.; Berns, A. For better or for worse: The role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer, 2011, 11, 23-34.
3. Narlik-Grassow, M.; Blanco-Aparicio, C.; Carnero, A. The PIM family of serine/threonine kinases in cancer. Med. Res. Rev., 2014, 34, 136-159.
4. Santio, N.M.; Vahakoski, R.L.; Rainio, E.M.; Sandholm, J.A.; Virtanen, S.S.; Prudhomme, M.; Anizon, F.; Moreau, P.; Koskinen, P.J. Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol. Cancer, 2010, 9, 279.
5. Magnuson, N.S.; Wang, Z.; Ding, G.; Reeves, R. Why target PIM1 for cancer diagnosis and treatment? Future Oncol., 2010, 6, 1461-1478.
6. Brault, L.; Gasser, C.; Bracher, F.; Huber, K.; Knapp, S.; Schwaller, J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica, 2010, 95, 1004-1015.
7. Brault, L.; Menter, T.; Obermann, E.C.; Knapp, S.; Thommen, S.; Schwaller, J.; Tzankov, A. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br. J. Cancer, 2012, 107, 491-500.
8. Kim, J.; Roh, M.; Abdulkadir, S.A. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer, 2010, 10, 248.
9. Xu, D.; Allsop, S.A.; Witherspoon, S.M.; Snider, J. L.; Yeh, J.J.; Fiordalisi, J.J.; White, C.D.; Williams, D.; Cox, A.D.; Baines, A.T. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis, 2011, 32, 488-495.
10. Asano, J.; Nakano, A.; Oda, A.; Amou, H.; Hiasa, M.; Takeuchi, K.; Miki, H.; Nakamura, S.; Harada, T.; Fujii, S.; Kagawa, K.; Endo, I.; Yata, K.; Sakai, A.; Ozaki, S.; Matsumoto, T.; Abe, M. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia, 2011, 25, 1182-1188.
11. Kim, K.; Kim, J.H.; Youn, B.U.; Jin, H.M.; Kim, N. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction. J. Immunol., 2010, 185, 7460-7466.
12. Nihira, K.; Ando, Y.; Yamaguchi, T.; Kagami, Y.; Miki, Y.; Yoshida, K. Pim-1 controls NF-kappaB signalling by stabilizing RelA/p65. Cell Death Differ., 2010, 17, 689-698.
13. Yang, Q.; Chen, L.; Neelapu, S.S.; Miranda, R.N.; Medeiros, L.J.; Gandhi, V. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood, 2012, 120, 3491-3500.
14. Yan, B.; Zemskova, M.; Holder, S.; Chin, V.; Kraft, A.; Koskinen, P.J.; Lilly, M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J. Biol. Chem., 2003, 278, 45358-45367.
15. Gu, J.J.; Wang, Z.; Reeves, R.; Magnuson, N.S. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene, 2009, 28, 4261-4271.
16. Kim, W.; Youn, H.; Seong, K.M.; Yang, H.J.; Yun, Y.J.; Kwon, T.; Kim, Y.H.; Lee, J.Y.; Jin, Y.W.; Youn, B. PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases. Radiat. Res., 2011, 176, 539-552.
17. Forshell, L.P.; Li, Y.; Forshell, T.Z.; Rudelius, M.; Nilsson, L.; Keller, U.; Nilsson J. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget, 2011, 2, 448-460.
18. Wood, N.T.; Meek, D.W.; Mackintosh, C. 14-3-3 Binding to Pim-phosphorylated Ser166 and Ser186 of human Mdm2-potential interplay with the PKB/Akt pathway and p14(ARF). FEBS Lett., 2009, 583, 615-620.
19. Linn, D.E.; Yang, X.; Xie, Y.; Alfano, A.; Deshmukh, D.; Wang, X.; Shimelis, H.; Chen, H.; Li, W.; Xu, K.; Chen, M.; Qiu, Y. Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. J. Biol. Chem., 2012, 287, 22959-22968.
20. Isaac, M.; Siu, A.; Jongstra, J. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. Drug Resist Updat., 2011, 14, 203-211.
21. Anizon, F.; Shtil, A.A.; Danilenko, V.N.; Moreau, P. Fighting tumor cell survival: Advances in the design and evaluation of Pim inhibitors. Curr. Med. Chem., 2010, 17, 4114-4133.
22. Drygin, D.; Haddach, M.; Pierre, F.; Ryckman, D.M. Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy. J. Med. Chem., 2012, 55, 8199-8208.
23. Arunesh, G.M.; Shanti, E.; Krishna, M.H.; Kumar, J.S.; Viswanadhan, V.N. Small molecule inhibitors of Pim1 kinase: July 2009 to February 2013 patent update. Expert. Opin. Ther. Patents, 2014, 24, 5-17.
24. Akué-Gédu, R.; Rossignol, E.; Azzaro, S.; Knapp, S.; Filippakopoulos, P.; Bullock, A.N.; Bain, J.; Cohen, P.; Prudhomme, M.; Anizon, F.; Moreau, P. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J. Med. Chem., 2009, 52, 6369-6381.
25. Letribot, B.; Akué-Gédu, R.; Santio, N.M.; El-Ghozzi, M.; Avignant, D.; Cisnetti, F.; Koskinen, P.J.; Gautier, A.; Anizon, F.; Moreau, P. Use of copper(I) catalyzed azide alkyne cycloaddition (CuAAC) for the preparation of conjugated pyrrolo[2,3-a]carbazole Pim kinase inhibitors. Eur. J. Med. Chem., 2012, 50, 304-310.
26. Sybylx2.1, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri 63144, USA.
27. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H.P.; Izmaylov, A.F.; Bloino, J.; Zheng, G.; Sonnenberg, J.L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery Jr., J.A.; Peralta, J.E.; Ogliaro, F.; Bearpark, M.; Heyd, J.J.; Brothers, E.; Kudin, K.N.; Staroverov, V.N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J.C.; Iyengar, S.S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, N.J.; Klene, M.; Knox, J.E.; Cross, J.B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R.E.; Yazyev, O.; Austin, A.J.; Cammi, R.; Pomelli, C.; Ochterski, J.W.; Martin, R.L.; Morokuma, K.; Zakrzewski, V.G.; Voth, G.A.; Salvador, P.; Dannenberg, J.J.; Dapprich, S.; Daniels, A.D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J.V.; Cioslowski, J.; Fox, D.J. Gaussian, Gaussian 09, Revision D.01, Inc., Wallingford CT, 2009.
28. Hohenberg, P.; Kohn, W. Inhomogeneous electron gas. Phys. Rev., 1964, 136, B864-871.
29. Kohn, W.; Sham, L.J. Self-consistent equations including exchange and correlation effects. Phys. Rev., 1965, 140, A1133-1138.
30. Lee, C.; Yang, W.; Parr, R.G. Development of the colle-salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. B, 1988, 37, 785-789.
31. Becke, A.D. Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys., 1993, 98, 5648-5652.
32. Trott, O.A.; Olson J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem., 2010, 31, 455-461.
33. Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kale, L.; Schulten, K. Scalable molecular dynamics with NAMD. J. Comp. Chem., 2005, 26, 1781-1802.
34. http://www.ks.uiuc.edu/Research/namd/
35. Brooks, B.R.; Brooks IIIrd, C.L.; Mackerell Jr., A.D.; Nilsson, L.; Petrella, R.J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A.R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Kuczera, W.I.K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R.W.; Post, C.B.; Pu, J.Z.; Schaefer, M.; Tidor, B.; Venable, R.M.; Woodcock, H.L.; Wu, X.; Yang, W.; York, D.M.; Karplus, M. CHARMM: The biomolecular simulation program. J. Comp. Chem., 2009, 30, 1545-1615.
36. Le Pecq, J.B.; Paoletti, C.A. Fluorescent complex between ethidium bromide and nucleic acids. J. Mol. Biol., 1967, 27, 87-106.
37. Dezhenkova, L.G.; Tsvetkov, V.B.; Shtil, A.A. Inhibitors of topoisomerases I and II: Chemical structure, mechanisms of action and the role in cancer chemotherapy. Russ. Chem. Rev., 2014, 83, 82-92.
38. Shchekotikhin, A.E.; Glazunova, V.A.; Dezhenkova, L.G.; Shevtsova, E.K.; Traven’ V.F.; Balzarini, J.; Huang, H.-S.; Shtil, A.A.; Preobrazhenskaya, M.N. The first series of 4,11-bis[(2- aminoethyl)amino]anthra[2,3-b]furan-5,10-diones: Synthesis and anti-proliferative characteristics. Eur. J. Med. Chem., 2011, 46, 213-218.
39. Kang, K.; Nho, C.W.; Kim, N.D.; Song, D.G.; Park, Y.G.; Kim, M.; Pan, C.H.; Shin, D.; Oh, S.H.; Oh, H.S. Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase. Int. J. Oncol., 2014, 45, 558-566.
40. Peng, Y.H.; Li, J.J.; Xie, F.W.; Chen, J.F.; Yu, Y.H.; Ouyang, X.N.; Liang, H.J. Expression of Pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients. PLoS One, 2013, 8, e76693.
41. Weirauch, U.; Beckmann, N.; Thomas, M.; Grünweller, A.; Huber, K.; Bracher, F.; Hartmann, R.K.; Aigner, A. Functional role and therapeutic potential of the Pim-1 kinase in colon carcinoma. Neoplasia, 2013, 15, 783-794.
42. Song, J.H.; Kraft, A.S. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT- 737. Cancer Res., 2012, 72, 294-303.
43. Borillo, G.A.; Mason, M.; Quijada, P.; Völkers, M.; Cottage, C.; McGregor, M.; Din, S.; Fischer, K.; Gude, N.; Avitabile, D.; Barlow, S.; Alvarez, R.; Truffa, S.; Whittaker, R.; Glassy, M.S.; Gustafsson, A.B.; Miyamoto, S.; Glembotski, C.C.; Gottlieb, R.A.; Brown, J.H.; Sussman, M.A. Pim-1 kinase protects mitochondrial integrity in cardiomyocytes. Circ. Res., 2010, 106, 1265-1274.
44. Morris, G.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Comp. Chem., 2009, 30, 2785-2791.
45. https://www.paramchem.org
46. Vanommeslaeghe, K.; MacKerell Jr, A.D. Automation of the CHARMM General Force Field (CGenFF) I: Bond perception and atom typing. J. Chem. Inf. Model., 2012, 52, 3144-3154.
47. Vanommeslaeghe, K.; Prabhu Raman, E.; MacKerell Jr., A.D. Automation of the CHARMM General Force Field (CGenFF) II: Assignment of bonded parameters and partial atomic charges. J. Chem. Inf. Model., 2012, 52, 3155-3168.
48. Mayne, C.G.; Saam, J.; Schulten, K.; Tajkhorshid, E.; Gumbart, J.C. Rapid parametrization of small molecules using the force field toolkit. J. Comput. Chem., 2013, 34, 2757-2770.
49. Liu, Y.; Agrawal, N.J.; Radhakrishnan, R. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to Pim1, Gsk-3β and CDK2/cyclin A protein kinases. J. Mod. Model., 2013, 19, 371-382.
50. Anastassiadis, T.; Deacon, S.W.; Devarajan, K.; Ma, H.; Peterson, J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotech., 2011, 29, 1039-1045.